Quarterly report · Q2

Period2021-12-01 → 2022-05-31
Filed2022-07-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥3.9bn2021-12-01 → 2022-05-31Cons.Net sales
Revenue¥7.9bn2020-12-01 → 2021-11-30Cons.Net sales (5-year summary)
Revenue¥3.9bn2020-12-01 → 2021-05-31Cons.Net sales
Operating income¥226m2021-12-01 → 2022-05-31Cons.Operating income
Operating income¥270m2020-12-01 → 2021-05-31Cons.Operating income
Ordinary income¥235m2021-12-01 → 2022-05-31Cons.Ordinary income
Ordinary income¥386m2020-12-01 → 2021-11-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥273m2020-12-01 → 2021-05-31Cons.Ordinary income
Profit before tax¥234m2021-12-01 → 2022-05-31Cons.Income before income taxes
Profit before tax¥273m2020-12-01 → 2021-05-31Cons.Income before income taxes
Net income (owners)¥179m2021-12-01 → 2022-05-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥281m2020-12-01 → 2021-11-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥195m2020-12-01 → 2021-05-31Cons.Profit loss attributable to owners of parent
Net income¥179m2021-12-01 → 2022-05-31Cons.Profit loss
Net income¥195m2020-12-01 → 2021-05-31Cons.Profit loss
Total assets¥7.8bnat 2022-05-31Cons.Assets
Total assets¥7.9bnat 2021-11-30Cons.Assets
Total assets¥7.6bnat 2021-05-31Cons.Total assets (5-year summary)
Total liabilities¥5.4bnat 2022-05-31Cons.Liabilities
Total liabilities¥5.6bnat 2021-11-30Cons.Liabilities
Net assets / equity¥2.4bnat 2022-05-31Cons.Net assets
Net assets / equity¥2.3bnat 2021-11-30Cons.Net assets
Net assets / equity¥2.2bnat 2021-05-31Cons.Net assets (5-year summary)
Cash and deposits¥984mat 2022-05-31Cons.Cash and deposits
Cash and deposits¥1.3bnat 2021-11-30Cons.Cash and deposits
Cash & equivalents¥984mat 2022-05-31Cons.Cash and cash equivalents
Cash & equivalents¥1.3bnat 2021-11-30Cons.Cash and cash equivalents
Cash & equivalents¥1.1bnat 2021-05-31Cons.Cash and cash equivalents
Cash & equivalents¥883mat 2020-11-30dCons.Cash and cash equivalents
Operating cash flow−¥124m2021-12-01 → 2022-05-31Cons.Net cash provided by used in operating activities
Operating cash flow¥785m2020-12-01 → 2021-11-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥388m2020-12-01 → 2021-05-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥121m2021-12-01 → 2022-05-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥246m2020-12-01 → 2021-11-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥109m2020-12-01 → 2021-05-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥104m2021-12-01 → 2022-05-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥119m2020-12-01 → 2021-11-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥78m2020-12-01 → 2021-05-31Cons.Net cash provided by used in financing activities
EPS (basic)¥147.062021-12-01 → 2022-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥68.822022-03-01 → 2022-05-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥230.992020-12-01 → 2021-11-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥160.32020-12-01 → 2021-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥95.622021-03-01 → 2021-05-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio30.6%at 2022-05-31Cons.Equity to asset ratio (5-year summary)
Equity ratio28.5%at 2021-11-30Cons.Equity to asset ratio (5-year summary)
Equity ratio28.5%at 2021-05-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue2021-12-01 → 2022-05-31¥3.9bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2021-12-01 → 2022-05-31¥3.9bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2021-12-01 → 2022-05-31¥211m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue2021-12-01 → 2022-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue external2021-12-01 → 2022-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentsegment profit2021-12-01 → 2022-05-31¥15m
Total Of Reportable Segments And Otherssegment totalrevenue2021-12-01 → 2022-05-31¥3.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-12-01 → 2022-05-31¥3.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-12-01 → 2022-05-31¥226m
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue2020-12-01 → 2021-05-31¥3.9bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2020-12-01 → 2021-05-31¥3.9bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2020-12-01 → 2021-05-31¥255m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue2020-12-01 → 2021-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue external2020-12-01 → 2021-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentsegment profit2020-12-01 → 2021-05-31¥15m
Total Of Reportable Segments And Otherssegment totalrevenue2020-12-01 → 2021-05-31¥3.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2020-12-01 → 2021-05-31¥3.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2020-12-01 → 2021-05-31¥270m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 477
ItemContextValueUnit
Number of shares heldCurrentQuarterInstant_No1MajorShareholdersMember201000
Shareholding ratioCurrentQuarterInstant_No1MajorShareholdersMember0.165
Number of shares heldCurrentQuarterInstant_No2MajorShareholdersMember121000
Shareholding ratioCurrentQuarterInstant_No2MajorShareholdersMember0.099
Number of shares heldCurrentQuarterInstant_No3MajorShareholdersMember28000
Shareholding ratioCurrentQuarterInstant_No3MajorShareholdersMember0.023
Number of shares heldCurrentQuarterInstant_No4MajorShareholdersMember25000
Shareholding ratioCurrentQuarterInstant_No4MajorShareholdersMember0.021
Number of shares heldCurrentQuarterInstant_No5MajorShareholdersMember25000
Shareholding ratioCurrentQuarterInstant_No5MajorShareholdersMember0.021
Number of shares heldCurrentQuarterInstant_No6MajorShareholdersMember24000
Shareholding ratioCurrentQuarterInstant_No6MajorShareholdersMember0.020
Number of shares heldCurrentQuarterInstant_No7MajorShareholdersMember20000
Shareholding ratioCurrentQuarterInstant_No7MajorShareholdersMember0.017
Number of shares heldCurrentQuarterInstant_No8MajorShareholdersMember20000
Shareholding ratioCurrentQuarterInstant_No8MajorShareholdersMember0.017
Number of shares heldCurrentQuarterInstant_No9MajorShareholdersMember20000
Shareholding ratioCurrentQuarterInstant_No9MajorShareholdersMember0.016
Number of shares heldCurrentQuarterInstant_No10MajorShareholdersMember16000
Shareholding ratioCurrentQuarterInstant_No10MajorShareholdersMember0.014
Number of shares heldCurrentQuarterInstant503000
Shareholding ratioCurrentQuarterInstant0.413
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of voting rights issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember2400
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember1213500
Number of voting rights issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember12135
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember4100
Number of shares issued shares voting rightsCurrentQuarterInstant1220000
Number of voting rights issued shares voting rightsCurrentQuarterInstant12135
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row1Member2400
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row1Member-
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member2400
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.002
Number of shares held in own name treasury shares etcCurrentQuarterInstant2400
Number of shares held in others names treasury shares etcCurrentQuarterInstant-
Total number of shares held treasury shares etcCurrentQuarterInstant2400
Shareholding ratio treasury shares etcCurrentQuarterInstant0.002
Cash and depositsPrior1YearInstant1319778000JPY
Cash and depositsCurrentQuarterInstant984133000JPY
Notes and accounts receivable tradePrior1YearInstant2562721000JPY
Notes and accounts receivable tradeCurrentQuarterInstant2510349000JPY
Merchandise and finished goodsPrior1YearInstant843220000JPY
Merchandise and finished goodsCurrentQuarterInstant983456000JPY
Work in processPrior1YearInstant300937000JPY
Work in processCurrentQuarterInstant424919000JPY
Raw materials and suppliesPrior1YearInstant325700000JPY
Raw materials and suppliesCurrentQuarterInstant434397000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2021-11-30pass
balance sheet identityconsolidated 2022-05-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-11-30pass
statement vs summary · net assetsconsolidated 2022-05-31pass
statement vs summary · net income attributable to parentconsolidated 2020-12-01/2021-05-31pass
statement vs summary · net income attributable to parentconsolidated 2021-12-01/2022-05-31pass
statement vs summary · operating cash flowconsolidated 2020-12-01/2021-05-31pass
statement vs summary · operating cash flowconsolidated 2021-12-01/2022-05-31pass
statement vs summary · revenueconsolidated 2020-12-01/2021-05-31pass
statement vs summary · revenueconsolidated 2021-12-01/2022-05-31pass
statement vs summary · total assetsconsolidated 2021-11-30pass
statement vs summary · total assetsconsolidated 2022-05-31pass